Evidence map›Paper›PMID 41484819›Full record

ArticleBMC bioinformatics2026

CMsiRNAdb: a database of chemically modified SiRNA silencing efficiency for nucleic acid drug design.

Sicheng He, Cheng Chen, Xianrun Pan, Gaogao Xue, Yu Yang, Juan Feng, Hasan Zulfiqar, Yang Zhang, Kejun Deng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sicheng He *School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Cheng Chen *School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Xianrun PanSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Gaogao XueAcademy for Interdiscipline, College of Medical Technology, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
Yu YangSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Juan FengSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China.
Hasan ZulfiqarState Key Laboratory of Common Mechanism Research for Major Diseases, Center for AI, Peking Union Medical College, Suzhou Institute of System Medicine, Chinese Academy of Medical Sciences, Suzhou, 215006, Jiangsu, China. hasanzulfiqar@ism.cams.cn.
Yang ZhangAcademy for Interdiscipline, College of Medical Technology, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China. zhy1001@alu.uestc.edu.cn.
Kejun DengSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China. dengkj@uestc.edu.cn.

Funding

Chengdu Health Commission-Chengdu University of Traditional Chinese Medicine Joint Research Fund WXLH202402041National Natural Science Foundation of China 62302079National Natural Science Foundation of China 62471071
6 · The paper itself

Abstract

backgroundSmall interfering RNA (siRNA) is a powerful tool for gene silencing, but its clinical application is limited by instability and potential immunogenicity. While chemical modification is essential to overcome these hurdles, data on chemically modified siRNAs are currently scattered, hindering rational drug design and development.

resultsWe developed CMsiRNAdb, a comprehensive database integrating data resources, analytical tools, and efficacy prediction for chemically modified siRNAs. We consolidated 43,153 experimentally validated sequences and silencing efficiency data derived from 90 patents, covering 36 modification types and 13 therapeutic target genes. The database offers multi-dimensional retrieval, visualization, and batch download functions. Furthermore, we developed ModMapper, a Trie tree-based tool for precise identification of modification sites, and integrated the Cm-siRPred model for efficacy evaluation. CMsiRNAdb is freely accessible at https://cellknowledge.com.cn/CMsiRNAdb/ .

conclusionCMsiRNAdb provides critical data support and analytical tools for the rational design and rapid optimization of siRNA drugs. By standardizing data and offering predictive capabilities, it significantly advances the development of nucleic acid therapeutics.

Indexed as

Databases, GeneticDrug DesignGene SilencingRNA, Small InterferingHumansRNA InterferenceSoftwareRNA, Small InterferingChemical modificationDatabaseEfficacy predictionNucleic acid drugsSilencing efficiencySiRNA

Identifiers

PMID41484819
PMCPMC12870949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.